Clinical trials: Malaria,Falciparum, open to volunteers
Malaria, Cerebral
DON in Pediatric Cerebral Malaria
The goal of this clinical trial is to evaluate the safety of a single intravenous dose of DON in healthy adults, adults with uncomplicated malaria, and children 12 months-14 years old with clinically defined Cerebral Malaria.
- Trial name
- NCT05478720
- Testing
- 6-diazo-5-oxo-L-norleucine (DON)
- Where
- 2 sites in Malawi
- Volunteers
- 152 people
- Sponsor
- Douglas Postels, MD, MS
Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)
This was Cohort C2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria.
- Trial name
- PLATINUM (NCT07811908)
- Testing
- KAE609, SoC (Coartem), KLU156
- Where
- 13 sites in Burkina Faso, Côte d’Ivoire and 5 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Malaria
Laboratory Evaluation of Pregnancy Malaria Vaccine Candidates/In-vitro Testing of Pregnancy Malaria Vaccine Candidates
Background: Malaria is a disease that affects many people in African countries. It is caused by germs that are spread by mosquito bites. It can be fatal if not diagnosed and treated right away.
- Trial name
- NCT02471378
- Where
- Mali
- Volunteers
- 7,476 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Plasmodium Vivax Malaria Without Complication, Plasmodium Falciparum Malaria (Uncomplicated)
Ethiopian Antimalarial Therapeutic Efficacy Study 2026
Background: The WHO recommends monitoring the efficacy of antimalarial drugs at least once every two years after implementation.
- Trial name
- TES2026 (NCT07840898)
- Testing
- Artemether-Lumefantrine + Primaquine and Chloroquine + Primaquine
- Where
- Ethiopia
- Volunteers
- 1,200 people
- Sponsor
- Ethiopian Public Health Institute
Malaria Vivax, Malaria Falciparum
Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar
The resilience of P. vivax to malaria elimination efforts is due to its ability to form dormant liver stages (hypnozoites) that reactivate weeks to months after the initial infection causing recurrent episodes of malaria…
- Conditions
- Malaria Vivax, Malaria Falciparum, Plasmodium Vivax, Plasmodium Falciparum
- Trial name
- PvSTATEM (NCT06923592)
- Testing
- PvSeroTAT, Control
- Where
- 2 sites in Ethiopia, Madagascar
- Volunteers
- 19,200 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Severe Malaria, Thrombocytopenia
Platelet-Directed Whole Blood Transfusion Strategy for Malaria
Open-label randomized controlled trial to test the effectiveness of whole blood transfusion for improving survival in children with severe malaria complicated by thrombocytopenia.
- Trial name
- PLATFORM (NCT05711485)
- Testing
- Whole blood transfusion
- Where
- 2 sites in United States, Zambia
- Volunteers
- 132 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Malaria, Asymptomatic Malaria
OPTIMAL LEAP: Optimizing Dihydroartemisinin-Piperaquine IPTsc Intervals to Advance Learning, Executive Function, Attendance, and Antimalarial Resistance Surveillance in Kenyan Schoolchildren
Malaria remains a major cause of illness among school-aged children in sub-Saharan Africa, many of whom carry asymptomatic Plasmodium falciparum infections that may contribute to anemia, inflammation, school absenteeism, and…
- Conditions
- Malaria, Asymptomatic Malaria, Intermittent Preventive Treatment
- Trial name
- Optimal LEAP (NCT07798583)
- Testing
- Monthly DP, Quarterly DP
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Indiana University
Malaria (Plasmodium Falciparum), Malaria Incidence
Insecticide-Treated Baby Wraps for the Prevention of Malaria
The objective is to test the protective effect of permethrin-treated and etofenprox-treated lesus against malaria in young children
- Trial name
- NCT07773350
- Testing
- Permethrin-treated lesu, Etofenprox-treated lesu, Untreated lesu
- Where
- Uganda
- Volunteers
- 1,296 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Malaria, PLASMODIUM FALCIPARUM MALARIA
Assessing Vaccine Effectiveness of R21/Matrix-M Across Malaria Transmission Settings (AVERT)
The AVERT study is a prospective observational test-negative case control study evaluating the real-world effectiveness of the R21/Matrix-M malaria vaccine among children younger than 5 years in Burkina Faso and Uganda.
- Trial name
- AVERT (NCT07749911)
- Testing
- R21/Matris-M Malaria vaccine
- Where
- 21 sites in Burkina Faso, Uganda
- Volunteers
- 20,000 people
- Sponsor
- Clinton Health Access Initiative Inc.
Plasmodium Falciparum Malaria, Malaria
R21/MM Dosing, Presentations, and Preservatives
This is a single blind randomised controlled trial (Phase 3 trial). This study aims to assess whether a half-dose of the R21/Matrix-M malaria vaccine is as effective as the full dose in children and adults.
- Conditions
- Plasmodium Falciparum Malaria, Malaria, Vaccine Reaction
- Trial name
- VAC100 (NCT07194668)
- Testing
- 10μg R21/50μg Matrix-M, 5μg R21/50μg Matrix-M with adaptor preservative free, 5μg R21/50μg Matrix-M with 2PE preservative
- Where
- 2 sites in Bangladesh
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria (Plasmodium Falciparum)
Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated Malaria
This study is investigating an innovative approach to treating uncomplicated malaria by adding a drug called Imatinib to the current standard of care, Artemether + Lumefantrine (AL).
- Trial name
- NCT07559370
- Testing
- Artemether lumefantrine tablets, Artemether Lumefantrine and Imatinib Mesylate
- Where
- Kenya
- Volunteers
- 1,116 people
- Sponsor
- Victoria Biomedical Research Institute
Malaria (Plasmodium Falciparum), Malaria Falciparum
Safety and PK of MMV371 LAI in Healthy Adults and Adolescents in Rwanda
This Phase 1b study will assess the safety, tolerability and pharmacokinetics (PK, this measures the levels of study drug in the body) of a single injection of MMV371 in healthy adult and adolescent participants in Rwanda.
- Conditions
- Malaria (Plasmodium Falciparum), Malaria Falciparum, Malaria Infection, Malaria Prophylaxis
- Trial name
- NCT07548021
- Testing
- MMV371
- Where
- Rwanda
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria Asymptomatic Parasitaemia, Malaria Falciparum
Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana
Previous malaria control studies in Ghana have shown that community-wide approaches can substantially reduce malaria infections.
- Conditions
- Malaria Asymptomatic Parasitaemia, Malaria Falciparum, Malaria Infection, Malaria Transmission
- Trial name
- NCT07389057
- Testing
- DHAP, Single low dose PQ
- Where
- Ghana
- Volunteers
- 9,000 people, healthy volunteers welcome
- Sponsor
- Noguchi Memorial Institute for Medical Research
Malaria, Falciparum
Perennial Malaria Chemoprevention in the Malaria Vaccine Era
Malaria remains a major cause of pediatric deaths and morbidity in Africa. An affordable malaria vaccine, R21, is being deployed in Uganda and other African countries with high malaria transmission, but efficacy is incomplete and…
- Trial name
- PMC-VAC (NCT07322068)
- Testing
- Sulfadoxine pyrimethamine + Amodiaquine, Dihydroartemisinin Piperaquine
- Where
- Uganda
- Volunteers
- 1,290 people, healthy volunteers welcome
- Sponsor
- Stanford University
Plasmodium Falciparum Malaria
Mass Vaccine and Drug Administration, Bangladesh
This is an open i.e. not blinded, cluster-randomised, controlled intervention study. The study will use a factorial design to estimate the protective effectiveness of mass drug administrations, mass vaccinations, combined mass…
- Trial name
- MVDA (NCT06068530)
- Testing
- DHA/piperaquine and a SLD-PQ, Study vaccine R21/Matrix-M™
- Where
- 2 sites in Bangladesh
- Volunteers
- 10,000 people
- Sponsor
- University of Oxford
Uncomplicated Plasmodium Falciparum Malaria
A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines
The goal of this open-label randomised, controlled, non-inferiority trial is to assess and compare the efficacy, tolerability and safety of a fixed dose TACT artemether-lumefantrine-amodiaquine (ALAQ) to the ACTs…
- Trial name
- FD-TACT (NCT05951595)
- Testing
- Artemether-Lumefantrine-Amodiaquine (ALAQ), Artemether-Lumefantrine (AL), Artesunate-Amodiaquine (ASAQ)
- Where
- Rwanda
- Volunteers
- 1,680 people
- Sponsor
- University of Oxford
Malaria
A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months
The purpose of this study is to evaluate the safety and immunogenicity of reduced antigen doses and alternative vaccination regimes for RTS,S/AS01E in healthy children aged 5-60 months in a malaria-endemic area.
- Trial name
- NCT07036159
- Testing
- RTS,S/AS01E vaccine
- Where
- 2 sites in Rwanda
- Volunteers
- 238 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria,Falciparum, Morality
An Observational Study to Assess Effectiveness and Safety of The R21/Matrix-M Malaria Vaccine
This is an observational case-control study to assess the effectiveness of the R21/Matrix-M vaccine against severe malaria, clinical malaria (in high transmission perennial areas), and to assess if the R21 vaccine recipients are…
- Trial name
- NCT07009847
- Testing
- Case control study of clinical malaria, Case control study of severe malaria, Case control study of death (all cause)
- Where
- 5 sites in Burkina Faso, Côte d’Ivoire and 2 more
- Volunteers
- 2,308 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria
Platform study to evaluate the efficacy and safety of anti-malarial agents in patients with uncomplicated Plasmodium falciparum malaria
- Trial name
- PLATINUM (NCT05750628)
- Testing
- INE963, KAE609 (Cipargamin), SoC (Coartem)
- Where
- 12 sites in Burkina Faso, Côte d’Ivoire and 4 more
- Volunteers
- 327 people
- Sponsor
- Novartis Pharmaceuticals